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ABSTRACT 
 
Quantitative Herd-level Evaluation of a Commercially Available Vaccine for Control of 
Salmonella in Dairy Cattle. 
 (December 2011) 
 
Russell Lee Farrow, B.S. Texas A&M University; 
 M.S., West Texas A&M University 
Co-Chairs of Advisory Committee: Dr. Guy H. Loneragan  
          Dr. Bo Norby 
 
 
 Salmonella continues to threaten public health as well as negatively impact dairy 
producers on multiple levels.  Efficacious solutions to control Salmonella among dairy 
cattle have long been sought to alleviate these problems.  A novel vaccine technology 
has been developed based on purified siderophore receptors and porin proteins (SRP®) 
derived from Salmonella Newport.  When vaccinated with these SRP® cattle are 
stimulated to produce antibodies which act in concert with host defenses to disrupt iron 
acquisition of pathogenic bacteria.  To evaluate the effectiveness of this technology, a 
prospective cohort study was designed utilizing herds (n = 11) that practiced whole herd 
vaccination with the SRP® vaccine (vaccinated cohort) and herds (n = 11) that had not 
used the SRP® vaccine.  Samples were collected during four rounds at approximately six 
week intervals from June through October 2009.  Samples were transported to the 
laboratory at West Texas A&M University and cultured for the prevalence of Salmonella 
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using selective enrichment methods.  Salmonella isolates were evaluated for 
antimicrobial susceptibility and serotype.  Data was analyzed using commercially 
available software to evaluate the herd-level effects of vaccination.   Salmonella was 
ubiquitous throughout the Texas Panhandle and Eastern New Mexico, within-herd 
animal level estimates of prevalence ranged from 0.0 – 92%, over the length of the study 
period.  Overall all rounds vaccinated herds had decreased (P = 0.012) Salmonella 
prevalence (15.3 vs. 27.5%).  Vaccinated herds had numerically fewer Salmonella 
isolates belonging to the Newport serotype.  Salmonella Typhimurium isolates were 
recovered approximately equally from vaccinated and non-vaccinated herds.  Isolates 
from vaccinated herds were resistant to fewer antimicrobials throughout the study 
period.  The ACSSuT(resistant to ampicillin, chloramphenicol, streptomycin, 
sulphisoxazole, and tetracycline) and MDR-AmpC (ACSSuT resistance plus resistance 
to ceftiofur and amoxicillin/clavulanate) resistant phenotypes were more frequently 
observed among non-vaccinated herds and none of the isolates from vaccinated or non-
vaccinated herds were resistant to nalidixic acid, gentamicin, ciprofloxacin, or amikacin.  
These findings indicate vaccine efficacy for the reduction of Salmonella prevalence.  
Dairy operators along with herd veterinarians are encouraged to utilize this data with 
other herd specific factors in determining whether to use this specific vaccine.   
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CHAPTER I 
INTRODUCTION 
 
Salmonella continues to be a critical area of concern amongst animal and public 
health officials alike.  As a result, dairy producers have sought efficacious vaccines to 
control Salmonella in dairy cattle.  Effective control of Salmonella in dairy cattle has the 
potential to decrease associated animal treatment cost, increase production parameters, 
and subsequently decrease the public health burden attributed to the consumption of 
Salmonella-contaminated beef products.  Therefore, the authors designed a prospective 
cohort study to evaluate the efficacy of a commercially available Salmonella Newport 
siderophore receptors and porin proteins (SRP®) vaccine in dairy cattle (AgriLabs, St. 
Joseph, MO).   
 The following dissertation provides a literature review (Chapter II) describing 
issues pertinent to Salmonella control from animal and public health perspectives.  
Chapters III & IV are products of the aforementioned study comparing herds vaccinated 
with the Salmonella Newport SRP® vaccine and non-vaccinated herds and will be 
presented as standalone manuscripts.  Previous studies have measured efficacy 
(comparisons of Salmonella prevalence) within individual herds and have yet to show a 
vaccine effect.  To the author’s knowledge, this will be the first study to evaluate this 
vaccine between vaccinated and non-vaccinated herds.  Chapter V will present 
significant cross-chapter conclusions. 
____________ 
This dissertation follows the style of the Journal of Food Protection. 
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CHAPTER II 
LITERATURE REVIEW 
 
History of Salmonella 
 Salmonella is named after Dr. Daniel E. Salmon, an American veterinary 
pathologist and USDA administrator.  Salmon was a graduate of Cornell University and 
was mentored by the French chemist Louis Pasteur (30).  In 1885, the genus Salmonella 
was discovered by Salmon’s research assistant Theobald Smith who had been 
investigating the cause of common hog cholera (38) and believed Salmonella to be the 
causal agent; however, this was later proven incorrect.  Since its discovery, the 
Salmonella genus has grown to include over 2,500 different serotypes.   
Salmonellosis is a worldwide public health concern, and wild and domestic 
animals and fowl have been shown to be reservoirs for Salmonella.  Transmission via 
ingestion of food and water contaminated with feces is regarded as the most common 
source of human infection; however, infection via direct contact with infected animals 
and fowl is also frequently reported.  Throughout many years of research and the 
discovery of new Salmonella serotypes, the nomenclature has become complex and 
considered by some as an ongoing area of debate.  Currently, the genus Salmonella is 
divided into two recognized species – Salmonella enterica and Salmonella bongori – 
with six main subspecies of enterica (I), salamae (II), arizonae (IIIa), diarizonae (IIIb), 
 houtenae (IV), and indica (VI), where Salmonella bongori was previously identified as 
subspecies V of Salmonella enterica.  Several Salmonella enterica subspecies enterica 
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serotypes have traditionally been found in specific species and are generally regarded as 
host adapted, typically causing systemic disease in a related group of animals.  For 
example, Typhi in humans, Cholerasuis in swine, Gallinarum in poultry, and Dublin in 
cattle, whereas other serotypes such as Enteritidis routinely produce systemic disease in 
a broad range of species, including cattle, swine, sheep, rodents, poultry, and humans 
(35).         
 Salmonella Typhi is believed to be the cause of death for multiple historical 
figures, including Alexander the Great in 323 B.C. as well as Prince Albert, husband of  
Queen Victoria, in 1861.  Additionally, historical scholars believe that a Salmonella 
Typhi outbreak was responsible for the deaths of more than 6,000 settlers at Jamestown, 
VA between 1607 and 1624.  Epidemics were also reported in the Spanish-American 
(1898) and South African (1899-1902) Wars (37).   
 Recent outbreaks of salmonellosis in humans have been linked to a variety of 
sources, including, but not limited to, dairy products, eggs, fruits, vegetables, meat, 
seafood, petting zoo animals, and reptiles.  In 1985, a salmonellosis outbreak was linked 
to more than 16,000 confirmed cases in 6 states (44).  This outbreak was determined to 
have been caused by the inadvertent mixing of raw and pasteurized milk at a Chicago 
dairy.  During 2000 and 2001, infants were admitted to hospitals exhibiting symptoms of 
salmonellosis and were culture positive for Salmonella believed to be contracted from 
reptiles maintained as family pets (37).  Salmonellosis in human populations is multi-
faceted.  Microbiological contamination, food preparation standards, and extrinsic 
factors such as cross-contamination of raw and cooked food products are potential 
4 
 
components that may result in human salmonellosis.  Fortunately, many of these issues 
are amendable to preventive activities, including pre-harvest and post harvest 
interventions and programs to educate consumers in safe food-handling procedures (39). 
Symptoms of salmonellosis include nausea, diarrhea, fever, chills, and abdominal 
cramping.  Symptoms usually persist between four and seven days with no sequelae.  
However, infections in immuno-compromised and immuno-suppressed individuals can 
develop into more serious complications; for example, children with sickle cell anemia 
can develop osteomyelitis.   
 Despite technological advances in the understanding of this bacteria as well as 
increased attention to prevent its transmission in the production of food products, 
Salmonella continues to cause significant morbidity and mortality in human and animal 
populations.  The CDC estimates that more than 1 million people suffer from 
salmonellosis each year, and of these afflicted people, approximately 500 die (29).   
 
Description of Salmonella 
 Salmonella is a genus composed of rod shaped, non-spore-forming, 
predominately motile, Gram-negative bacteria belonging to the Enterobacteriaceae 
family (15).  Gram staining shows straight rods ranging in length from 2.0 – 5.0 µm and 
0.7 - 1.5 µm in width with peritrichous flagella.  Most species produce hydrogen sulfide 
and are identified as black colonies when using an agar containing ferrous sulfate (4) 
such as xylose lysine deoxycholate (XLD), xylose lysine tergitol-4 (XLT4), and brilliant 
green agar (BGA).   As mentioned briefly above, two species are currently recognized in 
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the genus Salmonella: Salmonella enterica and Salmonella bongori.  Salmonella 
enterica is comprised of six subspecies: enterica (I), salamae (II), arizonae (IIIa), 
diarizonae (IIIb), houtenae (IV), and indica (VI) (24).  Salmonella enterica subspecies 
enterica (I) are usually isolated from humans and other warm-blooded animals, while 
subspecies II-VI and Salmonella bongori are usually isolated from reptiles and 
environmental sources (31).  Currently, significant resources have been directed towards 
and allocated to further understanding Salmonella enterica and how this subspecies 
infects cattle and subsequently humans via the consumption of contaminated meat and 
milk products.  This research will focus on the evaluation of subspecies Salmonella 
enterica supspecies enterica that infect the gastro-intestinal tract of dairy cattle that 
could potentially result in human cases of salmonellosis via consumption of 
contaminated beef products derived from culled dairy cows. 
 
Clinical Significance  
 In the United States, new cases of salmonellosis continues to be one of the top 
three bacterial foodborne illnesses (CDC estimated cases 1,400,000) along with 
Campylobacter (2,400,000) and E. coli O157:H7 (70,000).  Salmonella infections 
commonly result in fever, diarrhea, and severe abdominal cramping (29).  Among those 
that become infected, the young, elderly, and those with compromised immune systems 
are at the highest risk of severe infections as the organism can gain access to the blood 
stream resulting in life-threatening complications.  These persons may be at an increased 
risk of human to human transmission when they are exposed to such environments as 
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child and adult day cares as well as nursing home facilities.  Additionally, severe cases 
may develop reactive arthritis or Reiter’s syndrome, a chronic, long-term illness 
characterized by joint pain, painful urination, and eye irritation.  Children with sickle-
cell anemia have an increased likelihood to develop osteomyelitis as a result of 
Salmonella infection.  Healthy adults typically recover completely in 4-7 days and do 
not require treatment; however, those cases with severe diarrhea or systemic infection 
may require hydration with intravenous fluids and treatment with antimicrobial drugs 
(3).  The two primary methods of transmission include the ingestion of food products 
with sufficient quantities of viable bacteria to cause infection and by direct contact and 
inadvertent consumption of feces from Salmonella contaminated livestock, fowl, and 
reptiles.  It is believed that large quantities (100,000) of viable cells are required to cause 
infection; however, this would certainly depend on host susceptibility as well as 
pathogenicity of the Salmonella strain.  The first method of transmission is generally 
responsible for larger, more widely distributed outbreaks resulting from national food 
distribution chains, especially in the U.S., and it is estimated to be responsible for 85% 
of cases (17).  Moreover, many of these outbreaks, especially those caused by drug 
resistant phenotypes, have been linked to ground beef products.  The second method of 
transmission via direct contact with contaminated feces and subsequent ingestion gives 
rise to substantially fewer and more sporadic Salmonella cases and or outbreaks.     
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Salmonella in Dairy Cattle 
 Dairy cattle are known reservoirs for Salmonella and have been linked to human 
infections via consumption of contaminated food products (2, 45).  Most cattle infected 
with Salmonella are asymptomatic carriers shedding fewer than 2.0 x 102 CFU per gram 
of feces (12); however, other asymptomatic carriers have been shown to shed Salmonella 
at concentrations greater than 1.0 x 106 (12).  Asymptomatic (sub-clinical) carriers may 
develop into clinical cases typically as a result of environmental and management effects 
that combine to reduce host immunity.  As a result of subclinical infection, other cattle 
may be subsequently exposed to sufficient quantities of bacteria to cause infection (23); 
however, exactly what factors combine to produce clinical outbreaks are largely 
unknown.  Modern dairy farms house cattle at high densities resulting in accumulation 
of significant quantities of manure which represents a large reservoir of Salmonella on 
farm.  Many dairies remove feces using pen scrapers and or flush systems to clean pens 
and ramps; however, these methods cannot completely remove all feces, and 
contamination may persist.  Free stall housing systems are generally cleaned on a daily 
basis using specialized machines to clean bedding material as well as water to flush 
concrete ramps.  Dairy cows maintained in dry lot housing are similarly maintained, but 
to the authors knowledge not at the frequency at which free stall barns are cleaned, 
therefore the possibility of increased contamination exist.   Up to 50% of calves exposed 
to contaminated teats and pen floors during the first six hours of life may begin shedding 
Salmonella within 24 hours (23).  While clinical infections among healthy adult cows 
are infrequent, clinical infections among calves born into contaminated environments are 
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common and especially costly to producers due to treatment cost and an increase in 
death loss.  In many instances, dairy producers apply lime to pen floors to reduce 
bacterial growth especially in maternity and calving pens as a cost-effective means to 
prevent infections.  After removal from the maternity pen, multiple sanitation strategies 
are generally employed to decrease contamination from individual feed buckets and 
bottles via chemical sanitizers as well as hot water rinses (23).  Calves are also reared in 
individual hutches to decrease the potential for animal to animal transmission of 
pathogenic organisms.  Feeding waste milk from the sick cows may serve to further 
increase bacterial exposure among calves; however, this may potentially be mitigated 
either by pasteurizing waste milk or feeding a milk replacer.  Appropriate calf 
management including, the consumption of adequate amounts of high quality colostrum 
during the first 4-6 hours of life, are paramount in preventing a broad range of infections 
including Salmonella (23). 
 Many feed ingredients have been shown to be contaminated with Salmonella and 
are a likely source of continuous exposure for cattle (9).  Feed grown locally using 
wastewater produced from dairies has been shown to increase contamination versus 
crops grown using well water (9).  Ensiling crops at a pH of less than 4.5 can effectively 
reduce contamination by providing unfavorable growth conditions for Salmonella (23); 
however, some crops may not reach a pH of 4.5 and can potentially serve as a growth 
medium for Salmonella as well as clostridial organisms.   
 Endemic Salmonella infections on commercial dairies provide a means of 
contamination of both milk and meat products; i.e., milk produced as well as cows being 
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sold for slaughter and entering the domestic fresh meat supply.  Milk, by state laws, 
must be pasteurized prior to being sold for retail consumption thereby reducing its ability 
to deliver viable Salmonella to consumers.  Meat products derived from infected, cull 
dairy cows that may have been inadvertently contaminated through the harvest and 
fabrication processes are subject to a variety of control measures including carcass 
pasteurization and the application of organic acids to reduce and or eliminate pathogens, 
however, these systems have not completely eliminated pathogens resulting in the 
potential delivery of Salmonella-contaminated products to consumers.  Consumers have 
thus far proved inadequate of fully protecting themselves from these pathogens, and 
outbreaks have occurred.  Therefore, effective control of Salmonella on dairy farms may 
have a profound two-fold effect: 1) reduced incidence of salmonellosis on dairies, and 2) 
reduce the burden of Salmonella in ground beef and a proportionate reduction of 
salmonellosis in human populations.  
 
Vaccine Technology 
 Vaccines by definition are suspensions of dead, attenuated, or otherwise 
modified microorganisms that when inoculated stimulate immunity in the recipient via 
antibody production (43).  Historically, Salmonella vaccines have utilized live non-
pathogenic strains or strains that have been stripped of their ability to produce illness in 
the host but are capable of stimulating the production of protective antibodies.  Killed 
bacteria have also been used in an effort to obtain the same outcome.  However, these 
methods have proved largely unsuccessful in their attempt to control Salmonella in 
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cattle.  A novel subunit vaccine technology produced by purifying specific parts of 
pathogenic strains of Salmonella has been developed and enjoys broad acceptance 
among dairy producers as a result of increased milk production in vaccinated cows.  The 
following is a brief description of this new technology, being that this is novel and 
proprietary details of its exact mode of action are limited.  
All organisms require iron for cellular function (5).  Vertebrates use multiple 
mechanisms to bind, transport, and make iron available to cells.  Iron made available to 
vertebrates is actively acquired via host-produced proteins and subsequently acquired at 
the cellular level by transferrin and lactoferrin proteins.  When iron-loaded ferrin 
proteins encounter receptors at the cell, the iron is transferred into cell cytoplasm and 
subsequently used for cellular function.  Given that host cells require iron and have a 
strong affinity for binding available iron, this often results in an iron shortage for foreign 
cells (e.g. bacteria) within the host.  However, during infection bacteria acquire iron 
from the host via the production of siderophores which are responsible for active iron 
transport to these bacteria.  Within the host immune system, when pathogenic bacteria 
are encountered, host immune cells are stimulated to secrete lipocalin 2 (27).  This 
compound acts to sequester the siderophores and limit the amount of iron available to 
invading bacteria.  Where iron is freely available, bacteria use porin proteins, tube-
shaped proteins located on the outer surface of bacteria contained in the cell wall to 
transport iron into the cell; however, when iron shortages exists, as in a vertebrate, these 
bacteria must have specialized mechanisms with greater iron affinity than the host to, in 
effect, steal iron from the host organism (27).  This specialized mechanism involves the 
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release of siderophores which scavenge iron from host-specific bound iron; 
subsequently, siderophore receptors on the cell wall actively pass iron into the cell 
cytoplasm where it is utilized in intracellular functions by the bacteria (26, 34).  Without 
iron or the ability to essentially obtain iron from the host, these foreign and often 
pathogenic bacteria would be starved of iron and die.  Given the iron acquisition 
competition occurring within host animals, it is believed that by concentrating and 
inoculating host animals with siderophore receptor and porin proteins (SRP®), the host 
can be effectively immunized against these proteins thus providing an additional form of 
immunological resistance to pathogens that rely on these proteins for iron metabolism. 
Currently, a conditionally licensed Salmonella Newport SRP® vaccine consisting of 
purified siderophore receptors and porin proteins is available for use in dairy cattle as a 
means to reduce fecal shedding of Salmonella and clinical salmonellosis outbreaks on 
dairy farms.  Field trials involving vaccinated and non-vaccinated herds have not been 
conducted to determine the ability of the vaccine to reduce herd-level prevalence of 
Salmonella.   
 
Critical Review of Salmonella SRP
®
 Vaccine Trials 
 Salmonellosis continues to be an area of concern across all regions and sizes of 
dairy farms as well as a significant public health concern.  Given that this vaccine 
technology is quite new, there are currently no peer-reviewed published results regarding 
the efficacy of this vaccine in challenge models.  However the vaccine maker reports 
significant reductions in the occurrence of diarrhea as well as a significant reduction in 
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colony forming units per gram of feces in a poorly described challenge study posted on 
their web site.  Unfortunately, these results have not been subjected to peer review and 
published.  To the credit of the vaccine manufacturer, the author is aware of multiple 
challenge studies that are currently in the planning stages to further investigate the 
efficacy of this vaccine.  Additionally, to date, few large-scale field trials have been 
conducted to examine the efficacy of this Salmonella SRP® vaccine at the herd level.  To 
the author’s knowledge, a total of three peer-reviewed published studies are currently 
available, two dairy and one feedlot study examining the efficacy of this vaccine (10, 19, 
22).  Collectively these studies have largely shown little to no effect comparing 
Salmonella prevalence between vaccinates to non-vaccinates; regardless, each study will 
be described and reviewed to discuss potential shortfalls in study design and analysis. 
 In 2007, Hermesch et al. submitted a journal article describing a prospective 
cohort study consisting of 180 Holstein cows and heifers within a 1200-cow 
confinement dairy with a herd history of salmonellosis.  Cattle were randomly assigned 
to treatments and were either injected with the Salmonella Newport SRP® vaccine or a 
control solution 45-60 days prior to parturition with a second vaccine administration 14-
21 days prior to parturition.  Fecal and blood samples were collected at multiple intervals 
for isolation of Salmonella and for antibodies against Salmonella Newport, respectively.  
Binary data (Salmonella prevalence) were analyzed using logistic regression techniques.  
Over the study period, vaccinated had cohorts significantly greater milk production 
(1.14kg/d).  Cattle receiving the vaccine had significantly higher concentrations of 
circulating antibodies of Salmonella Newport; however, Salmonella Newport was not 
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recovered from fecal samples.  Additionally, Salmonella Agona was recovered from 
20.3% of cattle, but the likelihood of recovery was not significantly different between 
controls and vaccinates (22).  The second dairy study was conducted on two dairies in 
Ohio with a history of Salmonella enterica in 2006 by Heider et al.  Twenty-five percent 
of the mature cows from each herd were systematically randomized to serve as 
vaccinates while the remaining 75% of the herds served as non-vaccinated controls 
within 2 dairies.  Cattle belonging to the vaccinated group were vaccinated twice during 
the study period, once at day 0 followed by a booster on day 14.  It is important to note 
that the study on farm one was conducted in the fall of the year while on farm two the 
study was conducted during the summer months.  Fecal samples were collected at day 0, 
14, 28, and 70 for a total of four collections on each dairy.  Samples were examined for 
the presence of Salmonella via standard culture methods.  Mixed effect logistic 
regression models with a random effect to control for the effects of clustering within 
herd were employed.   Salmonella was recovered at all collection periods and no 
differences in prevalence were observed between vaccinates and controls at any of the 
four collection periods, prevalence throughout the sampling period was 7.1%.  Similarly, 
when analyzed across the four collection periods, no differences were observed in fecal 
Salmonella prevalence (19).   
 A third study conducted in 2008, by Dodd et al. at a commercial feedlot was 
designed to evaluate the SRP® vaccine in beef cattle (10).  Upon arrival to the feedlot, 
feeder cattle (227 -250kg) were allocated in pairs (replicates) to study pens. Twenty pens 
of cattle (approximately 79 head per pen) were utilized with 10 pens per treatment 
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group.  Cattle were vaccinated as per arrival protocol typical for feedlots in the region 
and animals in the vaccinated cohort were administered the Salmonella Newport SRP® 
vaccine while control animals were administered a placebo, vaccinates were maintained 
in separate pens.  An additional dose or placebo was administered 21 days post 
enrollment.  Fecal samples were collected from pen floors (25 per pen) at 0, 60, 120 
days, and immediately prior to harvest for a total of four collections.  Logistic regression 
models were developed to assess binary outcomes among vaccinates and controls.  There 
were no significant differences between vaccinates and controls in respect to fecal 
prevalence of Salmonella.  Overall prevalence of Salmonella was 10.2 and 10.9% in 
vaccinated and control cattle, respectively.  Likewise, mortality and morbidity were not 
significantly different between vaccinates and controls (10). 
 In both of the dairy studies and the feedlot study, only a portion of the animals on 
each farm were vaccinated; while this may provide control animals for analysis, this 
design may not fully address all aspects in determining the efficacy of this vaccine.  To 
eliminate the potential effects of herd immunity on determining vaccine efficacy, it may 
be necessary for larger studies to be conducted utilizing multiple dairies with whole herd 
vaccination and herds with no history of vaccinations with the Salmonella Newport 
SRP® in an effort to be able to determine what amount of variation is attributable to the 
herd level and to the individual cow level.  By gaining an understanding of how 
variation is portioned between and within herds, researchers may be better equipped to 
measure the true measure of association of the Salmonella Newport SRP® vaccine.  The 
author recognizes the difficulties that this type of design will present from logistical and 
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financial standpoints as well as the unique data analysis components that would be 
necessary to accurately determine the efficacy of this vaccine using a study design that 
would incorporate multiple herds.  However, this scenario may well be one of the few 
ways in determining the real world efficacy of such a vaccine.  Additionally, in the two 
dairy and one feedlot studies, Salmonella prevalence was relatively low (20.3, 7.1, and 
10.5%, respectively) and may have contributed to the observed outcomes of no 
difference.  Research has shown that prevalence and incidence rates can vary widely 
within and among dairies and have often sampled dairies in the summer months that 
have shown increased prevalence within herds, with the vast majority of cases being 
subclinical or asymptomatic (12, 45 ).   
Furthermore, a phenomenon known as herd immunity may also be a plausible 
explanation for the observed outcomes in these studies.  Herd immunity is a type of 
protection among the entire herd when a large proportion of the herd has been 
vaccinated, thereby in theory reducing the number of animals shedding pathogenic 
organisms such as Salmonella while also decreasing the number of animals that may be 
susceptible to infection.  This phenomenon also has the ability to introduce bias into 
study outcomes potentially obscuring a vaccine effect.  Additionally, questions have 
arisen as to whether this vaccine can be used as a means to prevent new cases or as a tool 
to help clear cases of salmonellosis (symptomatic or asymptomatic) in dairy cattle.  As 
previously mentioned, the author is aware of two studies in the planning stages designed 
to address these questions.  Answers to these questions will be beneficial to the producer 
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in an effort to reduce clinical salmonellosis as well as to downstream processors where 
food safety concerns are greatest. 
In an additional study conducted in our laboratory under the supervision of Guy 
Loneragan, cull dairy cows were sampled at local auction markets originating from herds 
vaccinated with the Salmonella Newport SRP® and non-vaccinated herds (28).  Cull 
cows are derived from the general herd and similar distributions are observed in the 
wider milking herd.  The dairies using the conditionally licensed Salmonella vaccine 
exhibited the lowest burden of Salmonella. Substantial variation in shedding not 
attributable to use of the vaccine was noted (i.e., non-vaccinated herds prevalence varies 
from ~15% to greater than 80%). That said, however, analysis indicates vaccination is 
associated with a 76% reduction in Salmonella shedding (RR= 0.24; P<0.01). While 
caution should be used when making inferences because the study was not designed to 
evaluate the vaccine, it does appear that 1) the vaccine holds distinct promise; 2) a herd-
level approach is most appropriate.  
 While the true measure of association between vaccinated and non-vaccinated 
cows and herds will be difficult to determine, these studies have produced results that 
will encourage their use on dairy farms as it relates to prevalence of Salmonella and the 
ability of this vaccine to increase milk production as shown in the Hermesch et al. (22), 
this study will undoubtedly pique the interest of dairy operators.  With more widespread 
use of the vaccine, researchers may more easily conduct trials to observe the efficacy of 
the vaccine. However, determining proper study design and analysis to account for 
variables between dairies will be challenging.  Perhaps an example of such a study 
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would be one that measures herd-level factors that may be associated with prevalence of 
Salmonella when measured at the cow level, rather than aggregated at the herd level.  
Measuring at the individual animal level may potentially be the best tool to determine 
vaccine efficacy as it is unlikely and generally recognized that Salmonella cannot be 
completely removed from herds.       
             
Objectives 
 The objectives of the current research effort were to 1) quantitatively determine 
whether a commercially available vaccine can effectively control the Salmonella burden 
on dairies; and 2) partition unexplained variation in Salmonella shedding to within- and 
between- herd dynamics.  These objectives will work to identify potential vaccine 
efficacy observed through wholly vaccinated herds whereas previous experiments 
utilizing different study designs have thus far remained unsuccessful.  By portioning the 
unexplained variation observed in the model further research will be better focused on 
particular areas where the greatest change may potentially be effected.   
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CHAPTER III 
EFFECTS OF A COMMERCIALLY AVAILABLE VACCINE AGAINST 
SALMONELLA ENTERICA SEROTYPE NEWPORT ON FECAL PREVALENCE 
OF SALMONELLA IN DAIRY COWS 
 
Introduction  
Salmonella continues to be a critical area of concern amongst animal and public 
health officials alike.  Human Salmonella infections cause approximately 1.4 million 
illnesses resulting in economic losses greater than 2.5 billion dollars in the United States 
(42).  Food-source attribution estimates indicate that approximately 10% of human 
salmonellosis cases are a result of consuming contaminated beef products (1).  
Additionally, multiple interstate Salmonella outbreaks have been attributed to the 
consumption of under-cooked ground beef contaminated with Salmonella (6, 7, 40).    
 Salmonellosis in dairy cattle can cause clinical and sub-clinical illness that can 
decrease herd production and increase herd health expenditures (48).  With an increasing 
frequency, clinical illnesses that develop as a result of Salmonella enterica infections are 
often difficult to treat by herd veterinarians due to a decrease in the susceptibility of the 
organisms to commonly used veterinary antimicrobials.  In an effort to mitigate these 
concerns and ultimately increase herd immunity to this pathogen, producers have sought 
efficacious vaccines to prevent salmonellosis within their herds.  To date, few traditional 
vaccines have been shown to effectively reduce the burden of Salmonella in dairy cattle.  
This is due in large part to the inability of traditionally produced, autogenous vaccines to 
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target more than a single serotype or strain.  Therefore, to control the vast array of 
Salmonella serotypes found in dairy cattle, new vaccine technology with the ability to 
act against multiple serotypes has been sought. 
 A novel vaccine was recently made available through a conditional license for 
the control of clinical salmonellosis caused by serotype Salmonella Newport.  This 
vaccine currently enjoys broad acceptance among dairy producers due in part to a study 
by Hermesch et al. that has shown a significant increase in daily milk production (22).  
The vaccine contains purified extracts of siderophore receptors and porin proteins 
(SRP®), which are specialized proteins found in the cell wall of Gram-negative bacteria.  
These proteins play a critical role in the acquisition of elemental iron necessary for cell 
survival.  The components of the vaccine work to induce an antibody response against 
SRP® to reduce the cells’ ability to acquire iron, resulting in a competitive disadvantage.  
Early reports (14) indicated that a vaccine targeting siderophores may have decreased 
fecal shedding and rectal temperatures of Holstein bull calves challenged with 
Salmonella Newport.  However, despite multiple investigations the efficacy of this 
vaccine technology to significantly reduce fecal prevalence of Salmonella in field trials 
has not been proven (19, 22).   
 Dairy farmers routinely cull cows as a means to recover salvage value for these 
animals.  Multiple reports have identified that a majority of dairy farms have at least 
some level of Salmonella prevalence within herds (16, 41).  Given the fact that, at some 
level of prevalence, culled dairy cattle are entering the abattoir with at least sub-clinical 
salmonellosis, pre-harvest intervention strategies aimed at reducing Salmonella 
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prevalence in dairy cattle are critically important to a systems-based, multi-faceted 
approach to food safety.  The cyclical nature of beef as well as milk prices has at times 
resulted in large sell offs of dairy herds in an attempt to control production, these large 
influxes of known Salmonella reservoirs represents a unique stress upon current post 
harvest intervention strategies and potentially the opportunity to overwhelm the current 
interventions.  Additionally, if dairy producers can reduce Salmonella prevalence in their 
herds, they will benefit from increased health and wellness within their herds.   
Previous research to determine the efficacy of this Salmonella Newport SRP® 
vaccine has been conducted within single dairy herds and has yet to show statistical 
differences between vaccinated and non-vaccinated cows.  These findings may be the 
result of a phenomenon called herd immunity, a type of protection among the entire herd 
when a proportion of the herd has been vaccinated, thereby in theory reducing the 
number of animals capable of transmitting or acquiring disease.  A study conducted by 
Loneragan et al. (28) evaluating cull cows originating from herds vaccinated with 
Salmonella Newport SRP® reported deceased prevalence relative to non-vaccinated 
herds.  A herd level approach including vaccinated and non-vaccinated herds will 
remove any potential effects related to herd immunity that may have occurred in 
previous research, while recognizing these results are not the product of an experiment 
but rather an observational study.  Therefore, the objectives of the current research effort 
were to 1) quantitatively determine whether a commercially available vaccine can 
effectively control the Salmonella burden on dairies; and 2) partition unexplained 
variation in Salmonella shedding to within- and between- herd dynamics.   
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Materials and Methods 
Cattle 
 To evaluate the effectiveness of this technology, a prospective cohort study was 
designed utilizing herds (n = 11) that practiced whole herd vaccination with the SRP® 
vaccine (vaccinated cohort) and herds (n = 11) that had not used the SRP® vaccine.  
Commercial dairy herds were voluntarily enrolled via consultations with herd 
veterinarians and herd managers in the Texas Panhandle and Eastern New Mexico.  
Herds were enrolled based on proximity, animal breed, and animal housing type.  Eight 
herds were enrolled with a majority of cows within these herds being Jersey, housed in 
free stall barns, while the remaining 14 herds consisted of a majority of Holstein cows 
housed in dry-lot facilities.  Dairies ranged in size from 500 to 6,000 head of milking 
cows.  Care was taken to collect samples from animals at or near peak lactation, but not 
to collect from the same cows in subsequent periods, as the purpose of the study was not 
to examine cow-level effects but rather herd-level responses.  Herds enrolled in this 
study were managed in accordance with typical practices and under typical conditions 
for dairies located in this region of the U.S. and were under the supervision of herd 
veterinarians. 
 
 
Study Design 
Using a prospective cohort design with repeated sampling, dairies in the Texas 
Panhandle and Eastern New Mexico were enrolled as either vaccinated (n = 11) or non-
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vaccinated (n = 11) herds to test the efficacy of a conditionally licensed Salmonella 
Newport SRP® vaccine.  To qualify as vaccinated, each herd must have employed a 
whole-herd approach to vaccination (two doses during dry period) and have used the 
vaccine continuously for at least the previous 12 months.  Due to circumstances beyond 
the control of the investigators two herds began vaccination regimens during the study 
period and were incorporated into the vaccinated cohort upon the completion of herd 
wide vaccination and is described in depth below.  Non-vaccinated herds qualified for 
study inclusion if the herds had not been vaccinated with the trial vaccine within the 
previous 12 months. 
 Each dairy was visited four times with approximately 6-week intervals between 
collections beginning June, 15 2009 and ending October, 27 2009.  At each visit, 50 
fecal samples (~ 50g) were obtained via rectal palpation with individual sleeves from 
cows in peak lactation that were locked in head restraints during the A.M. feeding 
period.  Across the four sampling periods, a total of 4,400 fecal samples were collected.   
  
Sample Size Determination 
 Sample sizes were calculated to detect a 55% reduction in the fecal prevalence of 
Salmonella attributable to the vaccine (α=0.05; β=0.20).  Cows within a herd are 
considered to be clustered or that they share some common features and therefore are 
expected to have dependence between observations within a cluster (herd).  When 
clustering is present in an experiment where one observes correlated binary outcomes of 
different cluster sizes, increasing the number of clusters is more critical than increasing 
23 
 
the number of observations within a single cluster.  To control for clustering, plausible 
bounds of shedding in the non-vaccinated group were set from 12.5-80% with an 
expected prevalence of 35%.  Using these constraints, 50 samples per herd would 
provide a precise estimate of the fecal prevalence of Salmonella.  Additional sample size 
calculations indicate that a total of 22 clusters were necessary to achieve sufficient 
statistical power.   
 
 Vaccination Protocol 
 The vaccine under consideration in this study was a conditionally licensed, 
commercially available Salmonella Newport bacterial extract vaccine containing 
Salmonella SRP®.  Label directions indicate that a vaccination of 2 mL should be 
administered subcutaneously ahead of the shoulder, and animals should be revaccinated 
in two to four weeks.  Additionally, dry cows and bred heifers should be vaccinated 
twice prior to parturition with annual boosters.  While the authors cannot verify that each 
cow on all 22 dairies were properly vaccinated, consultations with herd managers and 
herd veterinarians confirm that vaccination schedules had been followed for each of the 
vaccinated herds.  Where protocol deviations did occur, the observations and resulting 
data were included in the analysis under the vaccine status at which point the fecal 
samples were collected. 
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Sample Collection 
           Fecal samples (~ 50 g) were collected as above from restrained cows in head 
stalls and subsequently placed in sterile collection cups.  Appropriate cautions were 
taken to avoid contamination and maintain individual sample integrity.  Individual 
animal identification numbers and breed were recorded at the time of sample collection.  
Samples were placed on wet ice and transported to a laboratory at West Texas A&M 
University for qualitative and quantitative bacterial culture.     
 
Bacterial Culture Methods 
All fecal samples were processed the day of collection for qualitative analysis of 
Salmonella.  Five grams of feces were inoculated into 45 ml Rappaport Vassiliadis R-10 
broth (RV) and 5g into 45 ml tetrathionate broth (TT) and incubated at 42 °C for 24 h.  
The remaining portion of the sample was refrigerated for subsequent quantitative 
determination.  Following enrichment, 1 μl of each of the inoculants were streaked onto 
xylose lysine tergitol-4 (XLT4) agar and incubated for an additional 24 h at 37 °C.  Post-
incubation plates were examined for morphologically typical Salmonella colonies (black 
center); negative plates were maintained at room temperature for an additional 24 h and 
re-examined for morphological characteristics.  Single colonies from Salmonella isolates 
were sent to the reference laboratory at the University of Pennsylvania for serotype 
determination.  For quantification, fecal samples that yielded a positive outcome from 
either RV or TT were retrieved and 10 grams of each fecal sample was diluted in 90 ml 
of tryptic soy broth (TSB) with phosphate (30 g TSB, 2.31 g KH2PO4, 12.54 g K2HPO4 
l-1, final pH 7.2) and spiral plated onto XLT4 using a commercially available spiral 
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plater (Spiral Biotech Autoplate 4000, Advanced Instruments, Inc., Norwood, MA).  
Plates were incubated at 42 °C for 24 h after incubation morphologically typical 
Salmonella colonies were counted and concentrations calculated.   
 
Statistical Analysis 
 Data were electronically captured, examined for errors, and imported into 
commercially available software for analysis.  Descriptive statistics were calculated and 
the results presented below.  For model construction and evaluation, the comparison of 
Salmonella fecal prevalence (proportion of positive outcomes for each herd at each 
sampling period) was the outcome variable.  Categorical responses (Salmonella positive 
or negative outcomes) were modeled using logistic regression.  The fixed effects of 
vaccination status and collection round and the vaccination status by collection round 
interaction were included.  To account for clustering of cows within herds and repeated 
measures, R- and G-side random effects for dairy and round were also included in the 
model.  Appropriate model diagnostics were used to assess statistical assumptions and 
model fit.  Estimations of variance within and between herds were calculated. 
  
Results 
It was the intent of the investigators to maintain each of the 11 dairies within 
their assigned group; however, due to circumstances beyond the investigators’ control, 
two deviations to allocation occurred.  Two herds which began the study as non-
vaccinates began a Salmonella Newport SRP® vaccination program between rounds 2 & 
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3; therefore, each of the first two rounds from these dairies were included as non-
vaccinates in the data analysis.  Round 3 for one of these dairies was excluded from the 
analysis to allow a period of time for all animals within the herd to be vaccinated due to 
the large herd size; round 4 results from the newly vaccinated herds were included in the 
analysis as vaccinated herds.     
A total of 4,400 fecal samples were collected and 4,399 cultured for Salmonella 
with one sample lost.  A total of 4,249 observations were included in the analysis due to 
the aforementioned protocol deviations and the lost sample.  Across all rounds, a total of 
1,064 (24.2%) of samples were culture positive for Salmonella.  For rounds 1to 4, the 
crude prevalence was 17.2, 28.4, 32.9, and 18.3%, respectively.  Model adjusted (for 
study design and clustering) means for rounds 1to 4 were 13.7, 25.7, 31.5, and 14.6%, 
respectively (Table 3.1; note tables located in appendix B).  Model adjusted means and 
their respective 95% confidence limits are displayed in Figure 3.1 (note; figures located 
in appendix A).  Within-herd Salmonella prevalence among all dairies and across all 
sampling rounds ranged from 0.0-92.0%, Salmonella was recovered from all dairies 
during the study. 
Analysis indicated significant (P = 0.019) differences in prevalence among 
vaccinated and non-vaccinated herds.  Additionally, significant (P < 0.001) differences 
in prevalence were observed among sampling rounds as well as a significant (P = 
0.0001) vaccination status by sampling round interaction.  For rounds 1 and 3, 
prevalence was numerically lower among vaccinates (round 1, 10.7 vs. 16.6%; round 3, 
29.8 vs. 33.7%) compared to non-vaccinates; however, these differences were not 
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statistically significant (round 1, P = 0.14; round 3, P = 0.63).  Significant differences in 
mean prevalence between vaccinates and non-vaccinates were observed for rounds 2 and 
4.  For round 2, prevalence among vaccinates was significantly higher than non-
vaccinated herds (16.3 vs. 38.3%, P = 0.001).  Similarly, for round 4, a statistical 
difference (P = 0.001) was observed between the mean prevalence of vaccinated and 
non-vaccinated herds ((9.7 vs. 24.6%) Figure 3.2).   
To explore the seasonal variations in Salmonella prevalence over time, the data 
were also analyzed by collection month.  Prevalence was lowest (12.5%) during the first 
collection month (June) and increased until peaking in September at 33.1%.  During the 
final collection month (October) prevalence decreased to 14.7%.  Monthly mean values 
along with 95% confidence intervals are presented in Figure 3.3. 
Mean concentration of direct plated quantifiable Salmonella was 2.1 x 102 CFU / 
gram of feces and ranged from below detectable limits (2.0 x 102 CFU/g) to 6.1 x 102 
CFU/g.  Unfortunately, too few samples yielded quantifiable results to be included for 
further analysis (n=85).  To partition the variance to between- and within-herd dynamics 
the following random effects model was used to control for the effect of round and dairy 
(   ijkRoundDairyRoundDairyRoundRoundRoundSalm   4332210 ).  
Between-dairy variance accounted for 41.2% while within-herd variance accounted for 
58.8% of the observed variation in the model.  This was calculated by dividing the sum 
of the residual covariance (random intercept, covariance component, auto regressive and 
residual for the random effect) divided by the sum of the residual variance plus the 
logistic residual (π2/3). 
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 Discussion 
 To the author’s knowledge, the study reported here provides the first significant 
evidence indicating the efficacy of the Salmonella Newport SRP® vaccine in reducing 
Salmonella fecal prevalence among vaccinated herds.  While vaccinated herds differed 
significantly only during two sampling periods, all sampling periods showed numerical 
decreases in Salmonella prevalence amongst vaccinates.  In addition, these data further 
confirm findings (13) that illustrate seasonal fluctuations in prevalence.  Given these late 
summer and early fall spikes in prevalence, dairy operators may find it useful to employ 
more stringent sanitation practices during this period to limit the potential risks of a 
clinical outbreak during this period.  Furthermore, in an effort to reduce the number of 
sub-clinically infected animals entering the food chain, dairy operators may find it useful 
to investigate potential avenues to decrease the number of culled animals during these 
peaks, however, it is unlikely that in the interest of food safety alone dairy producers 
would be willing to adopt such a strategy.  Variance partitioning demonstrated that 
greater than half of the unexplained variation exists within dairies and that further 
research to understand herd-level factors that could be responsible for these findings is 
warranted.  In future research efforts farm level variables may be incorporated into the 
model to better understand herd-level factors that are associated with Salmonella 
prevalence.  
 These results are in contrast to previous research (10, 19, 22) that did not report 
an effect of vaccine on Salmonella prevalence.  The previous research, while well 
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designed had several factors that may have contributed to their outcomes of no 
differences.  First, among these three studies Salmonella prevalence was relatively low, 
potentially decreasing the ability to determine if Salmonella prevalence differences 
attributable to vaccine use existed.  Additionally, these studies utilized portions of the 
herds as cohorts and may have given rise to the phenomenon herd immunity, effectively 
reducing the number of cows that may become infected as well as the number of infected 
animals capable of transmitting disease.  These results, however, confirm earlier findings 
by Loneragan et al. (28) indicating decreased Salmonella prevalence among herds 
practicing whole-herd vaccination using the Salmonella Newport SRP® vaccine.  This 
study as well as the present research utilized a herd-level approach to determine vaccine 
efficacy.  This study design, while not conducted as an experiment but rather an 
observational study, may serve as an example to others who are investigating the 
efficacy of vaccines as well as other interventions that are applied at the herd level.  It 
should also be noted that behavior modification as a result of outcomes observed during 
the study period are possible such as those that occurred on the two dairies within this 
study are possible.  In retrospect, to maintain study design integrity it may be necessary 
to maintain confidentiality of results, however many study participants were inclined to 
participate because they would receive in essence free Salmonella  testing on a portion 
of their herds over a period of time.  
The authors are encouraged by the results of this study illustrating the ability of 
the vaccine to effectively reduce fecal prevalence of Salmonella in vaccinated herds, as 
well as evidence illustrating increased milk production (22) among vaccinates.   Given 
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these beneficial findings, we believe that careful consideration of the vaccine use by 
dairy operators and herd veterinarians is warranted as a cost-effective on-farm tool to 
reduce on-farm Salmonella burdens.  Most importantly, further research should evaluate 
the direct impacts that vaccination of dairy herds with the Salmonella Newport SRP® 
vaccine has on the public health burden associated with Salmonella contaminated beef 
products.   
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CHAPTER IV 
 
EVALUATION OF DIFFERENCES BETWEEN SALMONELLA SEROTYPES 
RECOVERED FROM HERDS VACCINATED WITH SALMONELLA 
NEWPORT SRP
®
 VACCINE AND NON-VACCINATED HERDS 
 
Introduction 
 Salmonella species are ubiquitous in the environment and can colonize and cause 
disease in a variety of food-producing animals and humans. Salmonella infections in 
humans and animals continue to be a driving force for concern among public and animal 
health officials alike. Confirmed clinical cases of salmonellosis in humans exceed 
40,000, with an estimated 500 deaths annually (29).  Concerns regarding specific 
serotypes routinely isolated in humans and livestock have frequently been described in 
popular press and of particular interest are serotypes Typhimurium, Enteriditis, and 
Newport.  These three serotypes alone account for nearly 50% of the 2009 confirmed 
cases of human salmonellosis (8).  Further challenging public health efforts to decrease 
the incidence of salmonellosis is that disease caused by drug resistant Salmonella is 
frequently more severe and results in greater mortality than drug-susceptible strains (20, 
21, 46, 47).  This concerns food animal producers and public health officials alike 
because a greater proportion of isolates recovered from clinically infected animals and 
humans are more drug resistant than that observed previously (11, 18).  For example, 
ceftiofur resistance among Salmonella was essentially undetectable until the mid 1990s 
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and is now observed in ~20% of isolates recovered from cattle and 5% of isolates 
recovered from humans were resistant to ceftriaxone (11, 18).  Despite ongoing 
arguments regarding specific factors that give rise to the increase of antimicrobial 
resistant bacteria, the problem persist as one of the greatest concerns to public health. 
 As public health officials struggle to control Salmonella outbreaks attributed to a 
variety of food products, dairy operators likewise direct considerable effort to control 
Salmonella within their herds to decrease associated healthcare cost, increase production 
parameters, and most importantly to ensure the delivery of pathogen free milk and meat 
products into commerce.  To achieve these goals dairy producers have long sought 
efficacious vaccines for the control of Salmonella.  Novel vaccine technology exploiting 
an animal’s immune function to interfere with the ability of Salmonella to uptake iron, 
essential for survival, has recently been made commercially available.  Although 
previous reports (19, 22) have not demonstrated significant differences in prevalence 
between vaccinated and non-vaccinated animals within herds; one of these reports has 
indicated a significant increase in milk production which consequently encouraged use 
among dairy operators.  Given that an increasing number of dairy operators are 
practicing whole-herd vaccination using the Salmonella Newport SRP® vaccine, 
researchers now have the opportunity to evaluate the effectiveness of the vaccine at the 
herd-level which has previously not been feasible. 
 Therefore, the objective of this study was to determine if differences exist in 
Salmonella serotypes and their respective antimicrobial resistance patterns in isolates 
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recovered from herds vaccinated with a commercially available Salmonella Newport 
SRP® vaccine and non-vaccinated herds.  
 
Materials and Methods 
 As detailed in the previous chapter a prospective cohort study was undertaken to 
evaluate the efficacy of a commercially available Salmonella Newport SRP® vaccine to 
reduce Salmonella  prevalence comparing dairies that practiced either whole herd 
vaccination with the SRP® vaccine or dairies that did not employ any Salmonella 
vaccine programs.  In short 22 dairies were enrolled and fecal samples were collected 
from cows at or near peak lactation four times at approximately six week intervals.  
Eleven herds were enrolled to each group, either vaccinated or non-vaccinated.  It was 
the intent of the investigators to maintain each of the eleven dairies within their assigned 
group; however, due to circumstances beyond the investigators control, two deviations to 
allocation occurred.  Two herds which began the study as non-vaccinates began a 
Salmonella Newport SRP® vaccination program between rounds 2 & 3; therefore, each 
of the first two rounds from these dairies were included as non-vaccinates in the data 
analysis.  Round 3 for one of these dairies was excluded from the analysis to allow a 
period of time for all animals within the herd to be vaccinated due to the large herd size; 
round 4 results from the newly vaccinated herds were included in the analysis as 
vaccinated herds.  Fecal samples were collected and transported to the laboratory at 
West Texas A&M University for bacterial culture.   
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Bacterial Culture and Serotyping 
Five grams of feces were inoculated into 45 ml Rappaport Vassiliadis R-10 broth 
(RV) and 5g into 45 ml tetrathionate broth (TT) and incubated at 42 °C for 24 h.  
Following enrichment, 1 μl of each of the inoculants were streaked onto xylose lysine 
tergitol-4 (XLT4) agar and incubated for an additional 24 h at 37 °C.  Post incubation 
plates were examined for morphologically typical Salmonella colonies (black center); 
negative plates were maintained at room temperature for an additional 24 h and re-
examined.  For Salmonella positive samples one distinct colony per sample was 
transferred onto tryptic soy agar (TSA) plates and incubated at 37 oC for 24 hours.  Post 
incubation a single, isolated colony was selected and subcultured onto TSA slants and 
incubated as above.  Incubated slants were then frozen (-80 oC) and forwarded to the 
Salmonella Reference Center at the University of Pennsylvania School of Veterinary 
Medicine for serotyping by standard techniques (25).  
 
Antimicrobial Susceptibility 
 Susceptibility to a panel of antimicrobial drugs was determined for all 
Salmonella positive isolates from qualitative culture and isolation using broth dilution 
susceptibility testing using vendor supplied plates (Sensititre, TREK Diagnostics).  
Isolates were evaluated for resistance to 14 antimicrobials including ampicillin, 
amoxicillin/clavulanate, ceftriaxone, chloramphenicol, ciprofloxacin, 
trimethoprim/sulphamethoxazole, cefoxitin, gentamicin, kanamycin, nalidixic acid, 
sulphisoxazole, streptomycin, tetracycline, and ceftiofur.  The minimum inhibitory 
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concentration (MIC) breakpoints of each antimicrobial agent were determined according 
to the breakpoints used by the National Antimicrobial Resistance Monitoring System 
(NARMS) and the CLSI (formerly NCCLS)-established guidelines for bacteria isolated 
from animals (32, 33). 
Three to five colonies from TSA plates were placed into 5 ml of sterile, de-
ionized water and adjusted to a 0.5 McFarland standard.  A 10-µl portion of the 
suspension was transferred to 11ml Mueller-Hinton broth and vortexed. An automated 
inoculator dispensed 50 µl of the culture into wells of the 96-well plates.  The plates 
were covered with the vendor-supplied covers and incubated at 35 oC for 18-24 h. Plates 
were manually read using the Sensititre manual viewer.  The MIC was recorded at the 
lowest concentration that inhibited visible growth.  
 
Data Analysis 
 Data were electronically captured, examined for errors, and imported into 
commercially available software for analysis.  Descriptive statistics were calculated and 
the results presented below.   
 
Results 
 A total of 1,012 Salmonella positive isolates were evaluated for antimicrobial 
susceptibility.  A majority of isolates, 92.3% were resistant to 3 or fewer antibiotics.  
Consequently, 7.7% of these isolates were resistant to 4 or more antibiotics with no 
isolate resistant to more than 11 antibiotics (Table 4.1).  Several phenotypes of concern 
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to public and animal health officials were observed in a small proportion of isolates.  
Isolates resistant to ampicillin, chloramphenicol, streptomycin, sulphisoxazole, and 
tetracycline (ACSSuT) accounted for 6.7% (n=68) of Salmonella isolates (Table 4.2) and 
the MDR-AmpC (ACSSuT resistance plus resistance to ceftiofur and 
amoxicillin/clavulanate) phenotype accounted for 4.6% (n=46, Table 4.2) of isolates 
recovered from all herds.  Notably, within the ACSSuT phenotype when comparing 
vaccinated herds to non-vaccinated herds Salmonella Newport accounted for 16 versus 
33 isolates whereas, Salmonella Typhimurium accounted for 9 versus 4 isolates, 
respectively.  Within the MDR-AmpC resistance phenotype, similar outcomes were 
noted between vaccinated herds and herds not vaccinated with the Salmonella Newport 
SRP® vaccine; serotype Newport (n = 39) accounted for a numerically higher number of 
isolates (26 versus 13) among non-vaccinated herds relative to vaccinated herds. These 
two serotypes accounted for the majority of the MDR-AmpC phenotypes (Table 4.3). 
 No Salmonella positive isolates were resistant to nalidixic acid, gentamicin, 
ciprofloxacin, or amikacin.  Additionally, only seven isolates from the non-vaccinated 
group were resistant to trimethoprim/sulphamethoxazole.  Salmonella isolates displayed 
the greatest percentage of resistance to sulphisoxazole (32.7%).  The antibiotics 
tetracycline, streptomycin, and ampicillin accounted for 12.0, 10.5, and 8.5%, 
respectively, of the observed resistance.  Additional antibiotic data is contained in Table 
4.6.  For all antibiotics, excluding those where no resistance was observed (n=4), 
vaccinated herds had fewer isolates resistant to these antibiotics (n=11, Table 4.6).  
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 A total of thirty nine named serotypes were observed across all sampling units 
(Table 4.4).  The top five most prevalent serotypes observed were Salmonella 
Montevideo, Mbandaka, Cerro, Meleagridis, and Newport (21.8, 10.4, 9.9, 7.9 and 7.7%, 
respectively).  Collectively the top 15 observed serotypes accounted for 90.1% of the 
Salmonella positive isolates recovered.  Additionally, 2.6% of isolates were classified as 
other; these isolates include rough-strain, un-named, and un-typable Salmonella positive 
isolates.  Within the top ten serotypes, vaccinated herds had numerically fewer isolates 
from serotypes Mbandaka, Meleagridis, Newport, Kentucky, and Anatum.  Non-
vaccinated herds had numerically fewer Salmonella positives from the following 
serotypes, Montevideo, Cerro, Newington, Uganda, and Muenster.  Additional 
differences for all observed serotypes are presented in Table 4.5.     
  
Discussion 
 While it was not within the scope of the objectives described in the original 
proposal, the investigators have described herein differences in serotypes and antibiotic 
resistance patterns that existed between herds vaccinated with the Salmonella Newport 
SRP® vaccine and herds that had not been vaccinated with this vaccine.  The data 
presented here are to be interpreted as descriptive observations with no statistical 
comparisons due to the fact that the intent of the original study was not designed to 
evaluate statistical differences in serotypes and or associated antimicrobial resistance 
patterns.  The authors however, believe these findings warrant consideration and further 
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research designed to evaluate the effects of the vaccine on observed serotypes and 
antimicrobial resistance.   
 Herds vaccinated with the Salmonella Newport SRP® vaccine had considerably 
fewer Salmonella Newport isolates. Additionally, markedly fewer isolates derived from 
vaccinated herds demonstrated ACSSuT or MDR-AmpC resistance phenotypes, largely 
a result of the decreased number of Newport isolates recovered from vaccinated herds.  
In addition to increased milk production (22); these findings represent added data that 
dairy operators may wish to consider when deciding to utilize this vaccine technology.  
By using this vaccine, dairy operators may likely recoup associated vaccination costs 
and therefore may be further inclined to utilize this resource in the interest of food 
safety.  If these findings can be confirmed in future research, this approach to increasing 
herd health and food safety should be considered as a meaningful pre-harvest tool by all 
industry stakeholders.   
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CHAPTER V 
CONCLUSIONS 
 
 The following are a list, highlighting the outcomes of the studies conducted 
examining the effects of a conditionally licensed Salmonella Newport SRP® vaccine. 
 
 Salmonella is ubiquitous throughout dairies located in the Texas Panhandle 
and Eastern New Mexico 
 Within dairy, animal level Salmonella prevalence ranged from 0-92% across  
all dairies 
 Salmonella prevalence follows a seasonal pattern, increasing throughout early 
summer months and peaking in late summer and early fall 
 Herds vaccinated with the Salmonella Newport SRP® vaccine had lower 
Salmonella prevalence compared to non-vaccinated herds (15.3 vs. 27.5%) 
throughout the study period 
 Model explained variance within dairies accounted for 76.2% of the model, 
while 23.8% of the model explained variance existed between dairies 
 Herds vaccinated with Salmonella Newport SRP® vaccine had numerically 
fewer Salmonella isolates of the serotype Newport 
 Herds vaccinated with Salmonella Newport SRP® vaccine were resistant to 
fewer antimicrobials  throughout the study period 
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 ACSSuT and MDR-AmpC resistance phenotypes were more frequently 
observed in non-vaccinated herds 
 
Given these results the author is encouraged and recommends that careful 
consideration should be given to the implementation of a Salmonella Newport SRP® 
vaccine to effectively reduce on farm prevalence of Salmonella and to increase milk 
production. 
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         APPENDIX A 
TABLE 3.1.  Raw and adjusted mean Salmonella prevalence (%) across sampling 
periods. 
Round 1 2 3 4 
Raw 17.2 28.4 32.9 18.3 
Model Adjusted 13.7 25.7 31.5 14.6 
 
 
TABLE 4.1. Quantity of antimicrobials to which resistance was observed in Salmonella 
isolates. 
Antimicrobials Frequency Percent 
0 650 64.23% 
1 257 25.40% 
2 18 1.78% 
3 9 0.89% 
4 2 0.20% 
5 2 0.20% 
6 12 1.19% 
7 9 0.89% 
8 12 1.19% 
9 36 3.56% 
10 3 0.30% 
11 2 0.20% 
MDRAmpC 46 4.55% 
ACSSuT 68 6.72% 
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TABLE 4.2. Salmonella serotypes by ACSSuT (resistant to ampicillin, chloramphenicol, 
streptomycin, sulphisoxazole, and tetracycline) and MDR-AmpC (ACSSuT resistance 
plus resistance to ceftiofur and amoxicillin/clavulanate) resistance phenotypes. 
Serotype ACSSuT MDR-AmpC 
S. Newport 49 39 
S. Typhimurium 13 3 
S. Agona 2 2 
S. Meleagridis 1 0 
S. Orion 1 0 
Degraded monophasic 1 1 
Rough strain 1 1 
Total 68 46 
 
TABLE 4.3.  Salmonella serotypes with ACSSuT (resistant to ampicillin, 
chloramphenicol, streptomycin, sulphisoxazole, and tetracycline) and MDR-AmpC 
(ACSSuT resistance plus resistance to ceftiofur and amoxicillin/clavulanate) phenotypes 
by herd vaccination status. 
Serotype ACSSuT MDR-AmpC 
Vaccination Status* 0 1 0 1 
S. Newport 33 16 26 13 
S. Typhimurium 9 4 1 2 
S. Agona 2 0 2 0 
S. Meleagridis 1 0 0 0 
S. Orion 1 0 0 0 
Degraded monophasic 0 1 0 1 
Rough strain 1 0 1 0 
Total 47 21 30 16 
*where 0=non-vaccinated, 1=vaccinated with Salmonella 
Newport SRP® vaccine 
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TABLE 4.4.  Salmonella serotype diversity and rank across all sampling rounds and 
herds. 
Serotype Frequency % Rank 
Montevideo 206 21.78 1 
Mbandaka 98 10.36 2 
Cerro 94 9.94 3 
Meleagridis 75 7.93 4 
Newport 73 7.72 5 
Kentucky 54 5.71 6 
Newington 49 5.18 7 
Uganda 39 4.12 8 
Muenster 32 3.38 9 
Anatum 29 3.07 10 
Typhimurium 29 3.07 11 
*Other 25 2.64 12 
Infantis 17 1.80 13 
Havana 16 1.69 14 
Nottingham 16 1.69 15 
Cubana 15 1.59 16 
Muenchen 12 1.27 17 
Senftenberg 12 1.27 18 
Barranquilla 7 0.74 19 
Agona 6 0.63 20 
Give 5 0.53 21 
Tennessee 5 0.53 22 
Bredeney 4 0.42 23 
Orion 3 0.32 24 
Schwarzengrund 3 0.32 25 
Alachua 2 0.21 26 
Amager 2 0.21 27 
Cambridge 2 0.21 28 
Derby 2 0.21 29 
Kinshasa 2 0.21 30 
Lexington 2 0.21 31 
Manila 2 0.21 32 
Agama 1 0.11 33 
Bietri 1 0.11 34 
Fresno 1 0.11 35 
Hato 1 0.11 36 
Liverpool 1 0.11 37 
Manhattan 1 0.11 38 
Newbrunswick 1 0.11 39 
Norwich 1 0.11 40 
* Includes rough strain, un-named and un-typable 
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TABLE 4.5.  Salmonella serotypes by herd vaccination status.  
Serotype Non-Vaccinated Vaccinated Non-Vaccinated, % Vaccinated, % 
Montevideo 92 114 20.18 23.27 
Mbandaka 68 30 14.91 6.12 
Cerro 35 59 7.68 12.04 
Meleagridis 57 18 12.50 3.67 
Newport 41 32 8.99 6.53 
Kentucky 41 13 8.99 2.65 
Newington 6 43 1.32 8.78 
Uganda 0 39 0.00 7.96 
Muenster 10 22 2.19 4.49 
Anatum 16 13 3.51 2.65 
Typhimurium 14 15 3.07 3.06 
*Other 16 9 3.51 1.84 
Infantis 7 10 1.54 2.04 
Havana 7 9 1.54 1.84 
Nottingham 0 16 0.00 3.27 
Cubana 2 13 0.44 2.65 
Muenchen 4 8 0.88 1.63 
Senftenberg 9 3 1.97 0.61 
Barranquilla 2 5 0.44 1.02 
Agona 6 0 1.32 0.00 
Give 3 2 0.66 0.41 
Tennessee 2 3 0.44 0.61 
Bredeney 4 0 0.88 0.00 
Orion 2 1 0.44 0.20 
Schwarzengrund 0 3 0.00 0.61 
Alachua 1 1 0.22 0.20 
Amager 2 0 0.44 0.00 
Cambridge 0 2 0.00 0.41 
Derby 2 0 0.44 0.00 
Kinshasa 1 1 0.22 0.20 
Lexington 2 0 0.44 0.00 
Manila 0 2 0.00 0.41 
Agama 1 0 0.22 0.00 
Bietri 1 0 0.22 0.00 
Fresno 0 1 0.00 0.20 
Hato 0 1 0.00 0.20 
Liverpool 1 0 0.22 0.00 
Manhattan 0 1 0.00 0.20 
Newbrunswick 1 0 0.22 0.00 
Norwich 0 1 0.00 0.20 
* Includes rough strain, un-named and un-typable 
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TABLE 4.6. Percentage and total number of Salmonella isolates resistant to each of the 
evaluated antibiotics by herd vaccination status. 
Antimicrobials Salmonella pos, % Salmonella pos, n Total 
Vaccination status 0 1 0 1   
Sulphisoxazole 17.89 12.45 181 126 307 
Tetracycline 6.52 4.64 66 47 113 
Streptomycin 6.82 2.96 69 30 99 
Ampicillin 5.34 2.57 54 26 80 
Chloramphenicol 5.24 2.27 53 23 76 
Augmentin 4.05 2.67 41 27 68 
Ceftriaxone 3.95 2.37 40 24 64 
Cefoxitin 2.96 2.27 30 23 53 
Ceftiofur 3.26 1.68 33 17 50 
Kanamycin 1.88 0.40 19 4 23 
Tri/Sulph 0.69 0.00 7 0 7 
Nalidixic acid,  0.00 0.00 0 0 0 
Gentamicin 0.00 0.00 0 0 0 
Ciprofloxacin 0.00 0.00 0 0 0 
Amikacin 0.00 0.00 0 0 0 
where 0=non-vaccinated, 1=vaccinated with Salmonella Newport SRP® vaccine 
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        APPENDIX B 
 
FIGURE 3.1.  Model adjusted Salmonella prevalence and 95% confidence intervals by 
sampling round. 
 
 
 
FIGURE 3.2.  Model adjusted Salmonella prevalence by sampling round and 
vaccination status. 
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FIGURE 3.3.  Model adjusted Salmonella prevalence and 95% confidence intervals by 
sampling month. 
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